Investigation into the efficacy and safety profile of oral small-molecule GLP-1 receptor agonists in type 2 diabetes and obesity: a systematic review and meta-analysis - Takeaways - MDSpire

Investigation into the efficacy and safety profile of oral small-molecule GLP-1 receptor agonists in type 2 diabetes and obesity: a systematic review and meta-analysis

  • By

  • Li Li

  • Dianpeng Shui

  • Xiong Zhang

  • Bing Tan

  • Yan Deng

  • July 7, 2026

  • 0 min

Share

  • 1

    This meta-analysis evaluated the efficacy and safety of oral small-molecule GLP-1 receptor agonists in adults with type 2 diabetes and obesity.

  • 2

    Oral small-molecule GLP-1RAs significantly reduced body weight, body mass index, waist circumference, fasting blood glucose, and HbA1c.

  • 3

    The likelihood of achieving weight loss of ≥5%, ≥10%, and ≥15% was significantly increased with oral small-molecule GLP-1RAs.

  • 4

    Treatment-emergent adverse events and overall adverse events were increased, particularly gastrointestinal events, but serious adverse events were not.

  • 5

    The findings support the potential role of oral small-molecule GLP-1RAs as effective therapies for weight reduction and glycemic control.

Original Source(s)

Investigation into the efficacy and safety profile of oral small-molecule GLP-1 receptor agonists in type 2 diabetes and obesity: a systematic review and meta-analysis

  • by Li Li, Dianpeng Shui, Xiong Zhang, Bing Tan, Yan Deng

  • July 7, 2026

Related Content

National Trends and Outcomes of Metabolic and Bariatric Surgery in Adolescents: Insights from the Israeli National Bariatric Surgery Registry

Phenotypic and genomic frameworks for precision pharmacotherapy in obesity: a narrative review

The mysterious case of Eli Lilly’s obesity drug